IntegraGen has launched two separate software-as-a-service (SaaS) tools designed to solve complex queries based on large-scale genomic data in real time, with the goal of assisting in patient diagnosis and management.
Sirius and Mercury combine high-performance computing power via technologies based on serverless big data analytics platforms and powerful search engines. Sirius and Mercury are intended to enable clinicians, pathologists, and genome researchers to perform large-scale clinical and scientific interpretation of genomic data—including whole exome, whole genome, and whole transcriptome—in a timeframe compatible with clinical decision-making.
Developed for Mendelian and oncology applications, Sirius was created to help researchers quickly and intuitively analyze sequencing data from individuals from one or more families to identify genes or variants of interest by testing all transmission hypotheses. Sirius is designed to provide researchers with ease of use and speed of analysis despite considerable volumes of data being analyzed.
Mercury, launched commercially on January 15, is a cloud-based biological interpretation tool for oncology that is intended to help pathologists and oncologists transform raw data obtained via high-throughput sequencing into a clinical molecular report for diagnostic and clinical use.
Mercury was developed, in part, through the Interpretation of Clinical Exome Project (ICE), an IntegraGen-led collaborative effort to develop an advanced scientific software program aiding in the interpretation of genome-sequencing data obtained from cancer patients. Joining IntegraGen as collaborators for ICE are Institut Gustave Roussy, a cancer center in Villejuif, France; Sogeti High Tech, a 100% subsidiary of Capgemini Group; and INSERM, the French National Institute of Health and Medical Research.
“We are enthused by the genomic interpretation tool IntegraGen recently offered us to test because it enables us to quickly and efficiently interpret large amounts of genomic data obtained following Exome & whole-RNA sequencing of tumors from patients with a variety of cancer types,” Ludovic Lacroix, PharmD, Ph.D., head of molecular screening for personalized medicine at Institut Gustave Roussy, said in a statement.
IntegraGen said Mercury minimizes the complexity, time, and cost associated with clinical interpretation and identification of variants of potential interest to professionals in their therapeutic management of patients—especially related to identifying clinical trials intended for a patient’s molecular profile.
According to IntegraGen, Sirius and Mercury couple the variants identified with current scientific data, publications, and clinical trial data with an interface designed to help users access genomic information most relevant to their queries. IntegraGen is featuring the two tools during the 9th “Assises de Génétique Humaine et Médicale” conference, to be held January 24–26 in Nantes, France.
“With Mercury and Sirius, IntegraGen is transforming the generation of large-scale sequencing data into actionable results, thus enabling the realization of the benefits of precision medicine,” stated Bérengère Genin, IntegraGen’s director of bioinformatics.
Based in Evry Genopole, France, IntegraGen also has an U.S. office in Cambridge, MA. Last week, the company said it finished 2017 with revenue of €6.247 million ($7.654 million), up 4% from €6.022 million ($7.378 million) in 2016.